<DOC>
	<DOC>NCT02627144</DOC>
	<brief_summary>This is a non-interventional, multicenter study to evaluate efficacy and safety of intravenous bevacizumab (Avastin) in combination with interferon alpha-2a immunotherapy for first-line treatment in participants with advanced and/or metastatic renal cell cancer (mRCC) in daily routine.</brief_summary>
	<brief_title>Bevacizumab in Metastatic Renal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Histologically confirmed advanced and/or metastatic renal cell cancer No contraindications for Avastin according to summary of product characteristics (SmPC)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Metastatic renal cell carcinoma</keyword>
	<keyword>Avastin</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>